JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Serum and plasma sphingolipids as biomarkers of chemotherapy-induced cardiotoxicity in female patients with breast cancer

  • 0Department of Medicine, Stony Brook University, Stony Brook, NY, USA; Cancer Center, Stony Brook University, Stony Brook, NY, USA.
Journal of Lipid Research +

|

April 6, 2025

|

April 6, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study identifies sphingolipids (SLs) as potential biomarkers for predicting Doxorubicin-induced cardiotoxicity in breast cancer patients, offering new diagnostic possibilities.

Area Of Science

  • Biochemistry
  • Oncology
  • Cardiology

Background

  • Doxorubicin (Dox) chemotherapy is effective but causes cardiotoxicity.
  • Lack of biomarkers hinders prediction and monitoring of Dox-induced cardiotoxicity.
  • Sphingolipids (SLs) play roles in chemotherapy response and cardiac health.

Purpose Of The Study

  • To investigate serum and plasma sphingolipids (SLs) as potential biomarkers for Doxorubicin cardiotoxicity in breast cancer (BC) patients.
  • To correlate SL levels with cardiac parameters assessed by echocardiography during anthracycline therapy.

Main Methods

  • Retrospective analysis of serum and plasma SLs from female BC patients undergoing anthracycline therapy.
  • Correlation of SL species (Cer, deoxydihydroCer, dihydrosphingosine) with cardiac parameters.
  • Comparison of SLs' prognostic value against pro-NT-BNP.

Main Results

  • Significant changes in plasma and serum SLs observed during therapy, reverting post-treatment.
  • Baseline SL levels correlated with adverse cardiac outcomes.
  • Serum sphingosine-1-phosphate (S1P), dihydroS1P, and plasma Cer showed prognostic value comparable to pro-NT-BNP, especially post-therapy.

Conclusions

  • Plasma and serum SLs show promise as prognostic and diagnostic biomarkers for Doxorubicin cardiotoxicity in BC patients.
  • SL measurements could expand beyond metabolic disorders for chemotherapy-induced cardiac monitoring.
  • Further research is warranted to validate SLs as clinical biomarkers for cardiotoxicity.

Keywords:

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers 01:19

64

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers 01:20

110

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Blood Studies for Cardiovascular System III: Serum Lipid Profile 01:25

135

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...